PL3638243T3 - Sposoby leczenia mielofibrozy związanej z nowotworem mieloproliferacyjnym i niedokrwistości - Google Patents
Sposoby leczenia mielofibrozy związanej z nowotworem mieloproliferacyjnym i niedokrwistościInfo
- Publication number
- PL3638243T3 PL3638243T3 PL18816685.4T PL18816685T PL3638243T3 PL 3638243 T3 PL3638243 T3 PL 3638243T3 PL 18816685 T PL18816685 T PL 18816685T PL 3638243 T3 PL3638243 T3 PL 3638243T3
- Authority
- PL
- Poland
- Prior art keywords
- anemia
- treatment methods
- myeloproliferative neoplasia
- myelofibrosis
- myelofibrosis associated
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 208000007502 anemia Diseases 0.000 title 1
- 206010028537 myelofibrosis Diseases 0.000 title 1
- 230000002071 myeloproliferative effect Effects 0.000 title 1
- 230000009826 neoplastic cell growth Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762519725P | 2017-06-14 | 2017-06-14 | |
| US201862679210P | 2018-06-01 | 2018-06-01 | |
| PCT/US2018/037213 WO2018231905A1 (en) | 2017-06-14 | 2018-06-13 | Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3638243T3 true PL3638243T3 (pl) | 2025-02-10 |
Family
ID=64660712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18816685.4T PL3638243T3 (pl) | 2017-06-14 | 2018-06-13 | Sposoby leczenia mielofibrozy związanej z nowotworem mieloproliferacyjnym i niedokrwistości |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20200101134A1 (pl) |
| EP (2) | EP4454707A3 (pl) |
| JP (2) | JP7496686B2 (pl) |
| CN (1) | CN111050770A (pl) |
| DK (1) | DK3638243T3 (pl) |
| ES (1) | ES2991738T3 (pl) |
| FI (1) | FI3638243T3 (pl) |
| HR (1) | HRP20241477T1 (pl) |
| HU (1) | HUE068733T2 (pl) |
| LT (1) | LT3638243T (pl) |
| PL (1) | PL3638243T3 (pl) |
| PT (1) | PT3638243T (pl) |
| RS (1) | RS66093B1 (pl) |
| SI (1) | SI3638243T1 (pl) |
| SM (1) | SMT202400437T1 (pl) |
| WO (1) | WO2018231905A1 (pl) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| FI3227675T3 (fi) | 2014-12-03 | 2023-05-25 | Celgene Corp | Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi |
| EP4190805A3 (en) | 2015-05-20 | 2023-08-16 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
| MX2019001043A (es) * | 2016-07-27 | 2019-09-26 | Acceleron Pharma Inc | Metodos y composiciones para el tratamiento de la mielofibrosis. |
| JP7051846B2 (ja) | 2016-11-10 | 2022-04-11 | ケロス セラピューティクス インコーポレイテッド | アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物 |
| KR20200109330A (ko) | 2018-01-12 | 2020-09-22 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법 |
| CA3098679A1 (en) | 2018-05-09 | 2019-11-14 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| CN112969471A (zh) * | 2018-10-31 | 2021-06-15 | 细胞基因公司 | 使用激活素-actrii配体陷阱治疗具有环状铁粒幼细胞的受试者中由极低、低或中等风险的骨髓增生异常综合征引起的贫血 |
| KR20220088699A (ko) | 2019-09-27 | 2022-06-28 | 디스크 메디슨, 인크. | 골수섬유증 및 관련 상태의 치료 방법 |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| BR112022020628A2 (pt) * | 2020-04-13 | 2022-11-29 | Celgene Corp | Métodos para tratamento de anemia usando uma armadilha de ligante de actriib e fedratinibe |
| JP2023528223A (ja) | 2020-05-13 | 2023-07-04 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体 |
| CN115551487A (zh) * | 2020-05-15 | 2022-12-30 | 细胞基因公司 | 使用ACTRIIB配体陷阱和mTOR抑制剂治疗贫血的方法和组合物 |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| WO2022271716A2 (en) * | 2021-06-21 | 2022-12-29 | Keros Therapeutics, Inc. | Methods of using activin receptor type ii signaling inhibitors |
| JP2024532831A (ja) * | 2021-08-19 | 2024-09-10 | ケロス セラピューティクス インコーポレイテッド | アクチビン受容体ｉｉ型シグナル伝達阻害剤を使用する方法 |
| WO2025137373A1 (en) * | 2023-12-19 | 2025-06-26 | Cellarity, Inc. | Disease detection systems and methods |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| JPH11502717A (ja) | 1995-04-11 | 1999-03-09 | ザ ジェネラル ホスピタル コーポレーション | 逆ツーハイブリッドシステム |
| EP2314617B1 (en) | 2004-07-23 | 2015-06-24 | Acceleron Pharma Inc. | ActRII receptor polypeptides |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| TWI432449B (zh) | 2007-02-02 | 2014-04-01 | Acceleron Pharma Inc | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| PT2340031T (pt) | 2008-08-14 | 2019-07-25 | Acceleron Pharma Inc | Armadilhas de gdf para uso no tratamento de anemia |
| RU2642302C1 (ru) | 2009-08-13 | 2018-01-24 | Акселерон Фарма Инк. | Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов |
| DK3875104T3 (da) | 2011-10-17 | 2025-02-03 | Acceleron Pharma Inc | Sammensætninger til behandling af ineffektiv erytropoiese |
| WO2015143403A1 (en) | 2014-03-21 | 2015-09-24 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis by inhibiting activin b and/or gdf11 |
| BR112016029226A2 (pt) | 2014-06-13 | 2017-10-17 | Acceleron Pharma Inc | métodos e composições para o tratamento de úlceras |
| FI3227675T3 (fi) | 2014-12-03 | 2023-05-25 | Celgene Corp | Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi |
| EP3294320A4 (en) * | 2015-05-13 | 2018-12-26 | Celgene Corporation | Treatment of beta-thalassemia using actrii ligand traps |
| CN116327952A (zh) * | 2015-08-04 | 2023-06-27 | 阿塞勒隆制药公司 | 用于治疗骨髓增生性病症的方法 |
| JP7072507B2 (ja) * | 2015-11-23 | 2022-05-20 | アクセルロン ファーマ インコーポレイテッド | 眼の障害を処置するための方法 |
| MX2019001043A (es) | 2016-07-27 | 2019-09-26 | Acceleron Pharma Inc | Metodos y composiciones para el tratamiento de la mielofibrosis. |
-
2018
- 2018-06-13 HU HUE18816685A patent/HUE068733T2/hu unknown
- 2018-06-13 LT LTEPPCT/US2018/037213T patent/LT3638243T/lt unknown
- 2018-06-13 WO PCT/US2018/037213 patent/WO2018231905A1/en not_active Ceased
- 2018-06-13 EP EP24186606.0A patent/EP4454707A3/en active Pending
- 2018-06-13 ES ES18816685T patent/ES2991738T3/es active Active
- 2018-06-13 PL PL18816685.4T patent/PL3638243T3/pl unknown
- 2018-06-13 EP EP18816685.4A patent/EP3638243B1/en active Active
- 2018-06-13 HR HRP20241477TT patent/HRP20241477T1/hr unknown
- 2018-06-13 SM SM20240437T patent/SMT202400437T1/it unknown
- 2018-06-13 RS RS20241154A patent/RS66093B1/sr unknown
- 2018-06-13 CN CN201880052595.1A patent/CN111050770A/zh active Pending
- 2018-06-13 FI FIEP18816685.4T patent/FI3638243T3/fi active
- 2018-06-13 JP JP2019569312A patent/JP7496686B2/ja active Active
- 2018-06-13 SI SI201831166T patent/SI3638243T1/sl unknown
- 2018-06-13 DK DK18816685.4T patent/DK3638243T3/da active
- 2018-06-13 PT PT188166854T patent/PT3638243T/pt unknown
- 2018-06-13 US US16/621,866 patent/US20200101134A1/en not_active Abandoned
-
2024
- 2024-02-27 JP JP2024027645A patent/JP2024075579A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT3638243T (pt) | 2024-10-31 |
| EP3638243A1 (en) | 2020-04-22 |
| LT3638243T (lt) | 2024-11-11 |
| RS66093B1 (sr) | 2024-11-29 |
| CN111050770A (zh) | 2020-04-21 |
| SI3638243T1 (sl) | 2025-03-31 |
| EP4454707A3 (en) | 2024-12-25 |
| WO2018231905A8 (en) | 2020-01-30 |
| DK3638243T3 (da) | 2024-10-28 |
| JP2020524139A (ja) | 2020-08-13 |
| HUE068733T2 (hu) | 2025-01-28 |
| JP7496686B2 (ja) | 2024-06-07 |
| FI3638243T3 (fi) | 2024-10-29 |
| WO2018231905A1 (en) | 2018-12-20 |
| EP3638243B1 (en) | 2024-08-07 |
| US20200101134A1 (en) | 2020-04-02 |
| EP3638243A4 (en) | 2021-03-17 |
| EP4454707A2 (en) | 2024-10-30 |
| JP2024075579A (ja) | 2024-06-04 |
| ES2991738T3 (es) | 2024-12-04 |
| HRP20241477T1 (hr) | 2025-01-03 |
| SMT202400437T1 (it) | 2024-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3638243T3 (pl) | Sposoby leczenia mielofibrozy związanej z nowotworem mieloproliferacyjnym i niedokrwistości | |
| EP3575643A4 (en) | SLIDING COMPONENT | |
| EP3575621A4 (en) | SLIDING COMPONENT | |
| EP3543569A4 (en) | SLIDING COMPONENT | |
| EP3680519A4 (en) | Sliding component | |
| DK3235830T3 (da) | Interleukin-15-proteinkompleks og anvendelse deraf | |
| EP3540274A4 (en) | SLIDING COMPONENT | |
| EP3527859A4 (en) | SLIDING COMPONENT | |
| DK3212255T3 (da) | Selvorienterende sprøjte og sprøjtegrænseflade | |
| LT3148579T (lt) | Anti-gitr antikūnai ir jų panaudojimo būdai | |
| DK3139979T3 (da) | Enhed, forstøver og fremgangsmåde | |
| EP3540275A4 (en) | SLIDING PART | |
| IL262776A (en) | Humanized anti-il-1r3 antibodies | |
| EP3197552C0 (en) | SKIN TREATMENT DEVICE WITH INTERCHANGEABLE PART | |
| EP3334429C0 (en) | HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR | |
| EP3653914C0 (en) | SLIDING PARTS | |
| PL3493812T3 (pl) | Połączenia imetelstatu i wenetoklaksu do leczenia ostrej białaczki szpikowej | |
| DK3302478T3 (da) | Pac-1 kombinations behandling | |
| IL265531A (en) | N 3 -cyclically substituted thienouraciles and use thereof | |
| TWI800561B (zh) | 毛髮處理方法 | |
| EP3627012A4 (en) | SLIDING COMPONENT | |
| EP3493821A4 (en) | METHOD OF TREATING THE RESPIRATORY TRACT | |
| DK3432901T3 (da) | Sekventiel antikræftbehandling | |
| GB201705960D0 (en) | Novel ligand and use thereof | |
| EP3434231A4 (en) | HIP BELT |